KRAS and pancreatic neoplasm: While this phase II study of single agent MEK inhibition with selumetinib in KRASG12R-mutant pancreatic tumors, which previously were reported to be associated with less favorable survival rates compared to other KRAS mutation, did not meet its primary endpoint, three patients had stable disease for more than six months.